首頁 > 市場調查報告書 > 製藥

眼科藥物

市場調查報告書

商品編碼

1750580

青光眼治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Glaucoma Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034

出版日期: 2025年05月13日 | 出版商:

Global Market Insights Inc. | 英文 162 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

2024年，全球青光眼治療市場規模達66億美元，預計2034年將以4.8%的複合年成長率成長，達到105億美元。這歸因於全球範圍內青光眼發生率的上升，尤其是在老年人群中。隨著全球人口老化，與年齡相關的眼部疾病病例日益增多，病情也愈發嚴重，促使人們更加需要早期診斷和長期照護。糖尿病和高血壓等慢性疾病——都是青光眼的重要風險因素——的發生率也在上升，這進一步加劇了不同人群對有效且持久治療方案的需求。

各國政府和衛生機構已開始專注於宣傳活動，推廣早期篩檢和常規眼科檢查，這有助於在早期發現青光眼。這導致青光眼治療的啟動人數顯著增加。市場也受益於新型藥物的採用，包括Rho激酶抑制劑和固定劑量聯合療法，這些藥物正在擴大治療方案並改善患者預後。此外，醫療基礎設施的改善和可支配收入的成長（尤其是在新興市場），使得眼科護理更加便捷，使更廣泛的人群能夠尋求及時、先進的青光眼治療。

市場範圍
起始年份	2024
預測年份	2025-2034
起始值	66億美元
預測值	105億美元
複合年成長率	4.8%

開角型青光眼仍是最常見的青光眼類型，佔全球病例的70%以上，2024年價值達54億美元。青光眼的治療重點在於控制眼壓 (IOP)，以防止不可逆轉的視神經損傷。大多數療法著重於幫助降低眼壓的藥物，包括BETA受體阻斷劑、α受體激動劑、碳酸酐酶抑制劑和前列腺素類似物。開角型青光眼病情發展緩慢，通常沒有明顯症狀，直到出現嚴重的視力喪失。其慢性特性意味著患者需要持續的長期護理，從而對藥物解決方案和定期監測服務產生了持續的需求。

前列腺素類似物透過促進液體引流來降低眼壓，在2024年佔據治療市場的最高佔有率，達到33.6%，預計到2034年將達到37億美元。前列腺素類似物療效顯著且副作用相對較輕，廣泛用於治療開角型青光眼。隨著老齡化人口的增加，預計這類藥物的需求將進一步攀升，尤其是在越來越多的患者選擇不含防腐劑且使用方便的眼藥水配方的情況下。

美國青光眼治療市場在2024年達到22.4億美元，預計2034年將以4.9%的複合年成長率成長。美國人口老化、認知度高，加上強大的醫藥創新力量，持續推動先進治療方案的需求。完善的醫療基礎設施支持早期診斷和處方藥的廣泛獲取，同時，臨床試驗和FDA核准的持續投入正在迅速擴大現有藥物儲備。保險覆蓋率的提高和優惠的報銷政策也進一步支持了老年人和高風險族群對青光眼治療方案的採用。

諾華、輝瑞、參天製藥、太陽製藥、Thea、愛爾康、西普拉、艾伯維、博士倫、Inotek Pharmaceuticals、Eyepoint Pharmaceuticals、梯瓦製藥、默克和 Grevis Pharmaceuticals 等公司正積極參與這一領域的競爭。為了確保在青光眼治療市場的競爭優勢，領先的公司正在大力投資研發具有更高療效和安全性的下一代療法。他們專注於固定劑量組合，以簡化治療方案並提高患者的依從性。透過合作夥伴關係和分銷網路擴展到高成長的新興市場是另一個關鍵策略。此外，各公司正在增強數位參與工具和遠端患者監控技術，以支持早期介入和持續護理。策略合作、產品線多元化和產品生命週期管理仍然是加強全球區域市場定位的關鍵。

產業生態系統分析
產業衝擊力
- 成長動力
  - 全球青光眼盛行率不斷上升
  - 治療介入的技術進步
  - 增加正在進行的青光眼治療臨床試驗和產品發布
  - 低度開發國家和發展中國家日益增強的眼科保健意識
- 產業陷阱與挑戰
  - 與藥物相關的副作用
  - 嚴格的監管要求
成長潛力分析
管道分析
監管格局
川普政府關稅
- 對貿易的影響
  - 貿易量中斷
  - 報復措施
- 對產業的影響
  - 供給側影響（原料）
    - 主要材料價格波動
    - 供應鏈重組
    - 生產成本影響
  - 需求面影響（售價）
    - 價格傳導至終端市場
    - 市佔率動態
    - 消費者反應模式
- 受影響的主要公司
- 策略產業反應
  - 供應鏈重組
  - 定價和產品策略
  - 政策參與
- 展望與未來考慮
未來市場趨勢
波特的分析
PESTEL分析

第4章：競爭格局

介紹
公司矩陣分析
公司市佔率分析
主要市場參與者的競爭分析
競爭定位矩陣
策略儀表板

第5章：市場估計與預測：按疾病類型，2021 - 2034 年

主要趨勢
開角型青光眼
閉角型青光眼
其他疾病類型

第6章：市場估計與預測：按藥物類別，2021 - 2034 年

主要趨勢
前列腺素類似物
BETA受體阻斷劑
α腎上腺素激動劑
碳酸酐酶抑制劑
其他藥物類別

第7章：市場估計與預測：按配方，2021 - 2034 年

主要趨勢
堅硬的
液體

第8章：市場估計與預測：按年齡層，2021 - 2034 年

主要趨勢
18歲以下
19 - 40
41 - 60
60歲以上

第9章：市場估計與預測：按配銷通路，2021 - 2034 年

主要趨勢
醫院藥房
零售藥局
網路藥局

第10章：市場估計與預測：按地區，2021 - 2034 年

主要趨勢
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 英國
- 法國
- 西班牙
- 義大利
- 荷蘭
亞太地區
- 中國
- 印度
- 日本
- 澳洲
- 韓國
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
中東和非洲
- 南非
- 沙烏地阿拉伯
- 阿拉伯聯合大公國

第 11 章：公司簡介

AbbVie
Alcon
Bausch & Lomb
Cipla
Eyepoint Pharmaceuticals
Grevis Pharmaceuticals
Inotek Pharmaceuticals
Merck
Novartis
Pfizer
Santen Pharmaceutical
Sun Pharmaceutical
Teva Pharmaceutical
Thea

簡介目錄

Product Code: 5210

The Global Glaucoma Treatment Market was valued at USD 6.6 billion in 2024 and is estimated to grow at a CAGR of 4.8% to reach USD 10.5 billion by 2034, attributed to the rising incidence of glaucoma worldwide, especially among older adults. As the global population continues to age, cases of age-related ocular disorders are becoming more frequent and severe, prompting a greater need for early diagnosis and long-term care. Chronic illnesses such as diabetes and hypertension-both significant risk factors for developing glaucoma-are also on the rise, which further contributes to increasing demand for effective and long-lasting treatment options across various demographics.

Governments and health agencies have started focusing on awareness campaigns to promote early screening and routine eye examinations, which is helping detect glaucoma at earlier stages. This has led to a notable rise in treatment initiations. The market is also benefiting from the adoption of novel drug classes, including Rho kinase inhibitors and fixed-dose combination therapies, which are expanding treatment alternatives and improving patient outcomes. Additionally, improving healthcare infrastructure and growing disposable incomes-especially in emerging markets-are making ophthalmic care more accessible, enabling a broader segment of the population to pursue timely and advanced glaucoma management.

Market Scope
Start Year	2024
Forecast Year	2025-2034
Start Value	$6.6 Billion
Forecast Value	$10.5 Billion
CAGR	4.8%

Open-angle glaucoma remains the most diagnosed form of the disease, accounting for more than 70% of global cases and valued at USD 5.4 billion in 2024. Treating glaucoma revolves around managing intraocular pressure (IOP) to prevent irreversible optic nerve damage. Most therapies focus on medications that help reduce IOP, including beta-blockers, alpha agonists, carbonic anhydrase inhibitors, and prostaglandin analogs. Open angle glaucoma condition develops slowly and often without obvious symptoms until significant vision loss occurs. Its chronic nature means patients require continuous and long-term care, creating sustained demand for pharmaceutical solutions and regular monitoring services.

Prostaglandin analogs, which help lower eye pressure by enhancing fluid drainage, commanded the highest share of the treatment market in 2024, making up 33.6% share and is projected to reach USD 3.7 billion by 2034. Their effectiveness and relatively mild side effect profile make them widely prescribed for managing open-angle glaucoma. With aging populations increasing, the demand for these medications is expected to climb further, particularly as more patients opt for preservative-free and user-friendly eye drop formulations.

U.S. Glaucoma Treatment Market generated USD 2.24 billion in 2024 and is set to grow at a 4.9% CAGR through 2034. The country's aging population and high awareness levels, coupled with the strong presence of pharmaceutical innovators, continue to fuel demand for advanced treatment options. A well-established healthcare infrastructure supports early diagnosis and widespread access to prescription therapies, while ongoing investments in clinical trials and FDA approvals are rapidly expanding the available drug pipeline. Increased insurance coverage and favorable reimbursement policies are further supporting treatment adoption among the elderly and high-risk groups.

Companies like Novartis, Pfizer, Santen Pharmaceutical, Sun Pharmaceutical, Thea, Alcon, Cipla, AbbVie, Bausch & Lomb, Inotek Pharmaceuticals, Eyepoint Pharmaceuticals, Teva Pharmaceutical, Merck, and Grevis Pharmaceuticals are actively competing in this space. To secure a competitive edge in the glaucoma treatment market, leading companies are investing heavily in R&D to develop next-generation therapies with improved efficacy and safety. They are focusing on fixed-dose combinations to simplify treatment regimens and improve patient adherence. Expanding into high-growth emerging markets through partnerships and distribution networks is another key strategy. Additionally, firms are enhancing digital engagement tools and remote patient monitoring technologies to support early intervention and ongoing care. Strategic collaborations, pipeline diversification, and product lifecycle management remain central to strengthening market positioning across global regions.

Chapter 1 Methodology and Scope

1.1 Market scope and definition
1.2 Research design
- 1.2.1 Research approach
- 1.2.2 Data collection methods
1.3 Base estimates and calculations
- 1.3.1 Base year calculation
- 1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
- 1.5.1 Primary sources
- 1.5.2 Data mining sources

Chapter 2 Executive Summary

2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

3.1 Industry ecosystem analysis
3.2 Industry impact forces
- 3.2.1 Growth drivers
  - 3.2.1.1 Growing prevalence of glaucoma disease worldwide
  - 3.2.1.2 Technological advancements in therapeutic interventions
  - 3.2.1.3 Increasing ongoing clinical trials and product launches for glaucoma treatment
  - 3.2.1.4 Growing awareness initiatives regarding eye care in underdeveloped and developing nations
- 3.2.2 Industry pitfalls and challenges
  - 3.2.2.1 Side effects associated with the drugs
  - 3.2.2.2 Stringent regulatory requirements
3.3 Growth potential analysis
3.4 Pipeline analysis
3.5 Regulatory landscape
3.6 Trump administration tariffs
- 3.6.1 Impact on trade
  - 3.6.1.1 Trade volume disruptions
  - 3.6.1.2 Retaliatory measures
- 3.6.2 Impact on the Industry
  - 3.6.2.1 Supply-side impact (raw materials)
    - 3.6.2.1.1 Price volatility in key materials
    - 3.6.2.1.2 Supply chain restructuring
    - 3.6.2.1.3 Production cost implications
  - 3.6.2.2 Demand-side impact (selling price)
    - 3.6.2.2.1 Price transmission to end markets
    - 3.6.2.2.2 Market share dynamics
    - 3.6.2.2.3 Consumer response patterns
- 3.6.3 Key companies impacted
- 3.6.4 Strategic industry responses
  - 3.6.4.1 Supply chain reconfiguration
  - 3.6.4.2 Pricing and product strategies
  - 3.6.4.3 Policy engagement
- 3.6.5 Outlook and future considerations
3.7 Future market trends
3.8 Porter's analysis
3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

4.1 Introduction
4.2 Company matrix analysis
4.3 Company market share analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

5.1 Key trends
5.2 Open angle glaucoma
5.3 Angle closure glaucoma
5.4 Other disease types

Chapter 6 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

6.1 Key trends
6.2 Prostaglandin analogs
6.3 Beta-blockers
6.4 Alpha adrenergic agonist
6.5 Carbonic anhydrase inhibitors
6.6 Other drug classes

Chapter 7 Market Estimates and Forecast, By Formulation, 2021 - 2034 ($ Mn)

7.1 Key trends
7.2 Solid
7.3 Liquid

Chapter 8 Market Estimates and Forecast, By Age Group, 2021 - 2034 ($ Mn)

8.1 Key trends
8.2 Below 18
8.3 19 - 40
8.4 41 - 60
8.5 Above 60

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

9.1 Key trends
9.2 Hospital pharmacies
9.3 Retail pharmacies
9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

10.1 Key trends
10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
10.3 Europe
- 10.3.1 Germany
- 10.3.2 UK
- 10.3.3 France
- 10.3.4 Spain
- 10.3.5 Italy
- 10.3.6 Netherlands
10.4 Asia Pacific
- 10.4.1 China
- 10.4.2 India
- 10.4.3 Japan
- 10.4.4 Australia
- 10.4.5 South Korea
10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Argentina
10.6 Middle East and Africa
- 10.6.1 South Africa
- 10.6.2 Saudi Arabia
- 10.6.3 UAE